Physician profile
Patrick A Oruwari
NPI 1952396863
$7,763.60
in general payments reported to CMS, 2019-2025
31 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $750 · 2021: $1,216 · 2022: $938 · 2023: $1,245 · 2024: $807 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,285 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,284.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,217.95 | 2019-2025 | Ingrezza |
| Abbvie INC. | $1,107.98 | 2021-2025 | |
| Alkermes, INC. | $903.06 | 2019-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $390.43 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $382.03 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $367.24 | 2019-2025 | Invega Sustenna, Invega, Invega Trinza |
| Neos Therapeutics, Lp | $354.09 | 2019-2021 | |
| Harmony Biosciences LLC | $348.72 | 2025 | |
| Vanda Pharmaceuticals INC. | $287.19 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $257.27 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $245.31 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $211.71 | 2019-2022 | |
| Allergan, INC. | $160.63 | 2020 | |
| Braeburn INC. | $102.62 | 2024-2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $79.13 | 2024-2025 | Cobenfy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $42.83 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $37.04 | 2019 | |
| Collegium Pharmaceutical, INC. | $35.52 | 2025 | Jornay Pm |
| Amgen INC. | $33.27 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $27.24 | 2019 | |
| Abbott Laboratories | $26.01 | 2024 | Freestyle Libre |
| Axsome Therapeutics, INC. | $18.73 | 2023 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $18.61 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $17.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2022 | |
| Merck Sharp & Dohme LLC | $14.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $13.38 | 2019 | |
| Janssen Biotech, INC. | $13.08 | 2023 | |
| Indivior INC. | $12.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.81 | 2019 | |
| Acadia Pharmaceuticals INC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Oruwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.